Cipla, one of the leading Pharmaceutical companies has announced their partnership with Premier Medical Corporation Pvt Ltd today. The duo have created and are ready to launch their COVID-19 Rapid Antigen Test Kits in India. Cipla will control the marketing and distribution for the same. The test will detect SARS-Cov-2. The test is said to be 98.09% specific and upto 75% sensitive to provide accurate results. The nasopharyngeal swab tests supply will start this week.